CF is an autosomal recessive disorder caused by different mutations in the CF-associated gene encoding the CFTR protein (see URLs) 1 . Presently, various pharmacological agents that target specific classes of CFTR mutations to address dysfunctional CFTR activities in CF improve CFTR function and alter the disease process 2 . These agents generally come in two classes: potentiators and correctors. The former promote an increase in the residual activity of mutant CFTR proteins, whereas the latter promote proper folding or trafficking of mutant CFTR to increase its activity. The p.Phe508del mutation in the first nucleotide-binding domain, which is the most common mutation among individuals with CF, results in the production of a misfolded protein with residual activity that is degraded by the ubiquitin-proteasome system during biogenesis 2, 3 . Corrector drugs rescue trafficking of p.Phe508del-CFTR to the plasma membrane by directly targeting the mutant protein [2] [3] [4] . However, in spite of their high efficacy in vitro, CFTR correctors show modest clinical benefits in individuals with CF who harbor the p.Phe508del mutation, even when these correctors are combined with the CFTR potentiator ivacaftor 5, 6 . Given the complex molecular and cellular defects that occur in CF, a multidrug approach is desirable to both rescue and stabilize p.Phe508del-CFTR in vivo and, hence, prevent the progressive decline of lung function in most individuals with CF 7 . Recently, general strategies aimed at improving the proteostasis network by means of proteostasis regulators have emerged as an alternative approach to promote p.Phe508del-CFTR plasma membrane targeting and stability 8, 9 . Instead of directly targeting the mutant protein, proteostasis regulators favor p.Phe508del-CFTR rescue and stability by altering signaling pathways and checkpoints in cellular proteostasis [8] [9] [10] .
Optimal CF treatments should not only rescue CFTR localization and functionality but also alleviate the associated hyperinflammatory pathology 2, 8 . Rescuing chloride channel activity might be sufficient per se to reverse the inflammatory pathology in chronic CF lung disease 11, 12 . However, the complexity of the p.Phe508del-CFTR molecular defect makes this task challenging. Irrespective of whether the inflammatory response is due to multiple, additive effects-including chronic infection-or is a primary outcome of CFTR dysfunction, a hyperinflammatory state in individuals with CF is associated, as a rule, with early and nonresolving activation of innate immunity, which impairs microbial clearance and promotes a self-sustaining condition of progressive lung damage 13 . The remarkable persistence of chronic lung infections in the face of intensive antibiotic therapy 14 and, likewise, the major side-effects of both corticosteroids 15 and nonsteroidal anti-inflammatory drugs (NSAIDs), including inhibition of the CFTR chloride channel 16 , have revealed the need for therapeutic approaches aimed at activating early anti-inflammatory pathways to prevent, rather than correct, organ damage before patients become symptomatic. Moreover, hyperinflammatory mucosal responses to either cell-autonomous or environmental (for example, bacterial) stresses can further compromise cellular proteostasis, thus affecting CFTR trafficking and function in a feed-forward loop 10 . Therefore, the ideal anti-inflammatory drug in CF should be one that not only interrupts the vicious CF cycle that sustains inflammation but also generates favorable conditions for CFTR trafficking. To date, no single drug is available with such positive pleiotropic effects in individuals with CF.
Tα1 is a naturally occurring polypeptide of 28 amino acids 17 whose mechanism of action as an immune modulator presumably involves an ability to signal through innate immune receptors 18 that are activated by dynamic association with membrane phosphatidylserine 19 . Tα1 (Zadaxin) is used worldwide as an immunomodulator in viral infections, immunodeficiencies, malignancies and HIV/AIDS 20 . Owing to its ability to activate the tolerogenic pathway of tryptophan catabolism via the immunoregulatory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) 21 , Tα1 specifically potentiates immune tolerance in the lung, often breaking the vicious circle that perpetuates chronic lung inflammation in response to a variety of infectious noxae 18 . This led us to hypothesize that administration of Tα1 could be beneficial in CF to alleviate inflammation at an early stage of the disease and/or in individuals who are newly diagnosed. Here we report that Tα1 is endowed with a unique property consisting of a dual ability to control inflammation and rectify the functional defects of p.Phe508del-CFTR.
RESULTS

Ta1 improves inflammation and immune tolerance in CF
Inflammation plays a critical role in lung disease development and progression in CF. IDO1, which is known to inhibit pathogenic T helper type 17 (T H 17) cell activation and to initiate immune tolerance mechanisms in the lungs 21 , is defective in individuals with the p.Phe508del mutation in CFTR 22 . In accordance with an ability to induce IDO1 via Toll-like receptor 9 (TLR9) signaling 18 , Tα1 promoted colocalization of TLR9 with lysosomes ( Fig. 1a) , where maturation and signaling of TLR9 occur in response to stimulatory CpG oligodeoxynucleotides (ODN) 23 . Concomitantly, Tα1 rescued defective IDO1 expression in an airway epithelial cell line (CFBE41o-) stably expressing p.Phe508del-CFTR 24 (Fig. 1b) . In doing so, Tα1 reduced proinflammatory nuclear factor (NF)-κB activity in response to the TLR2 ligand MALP-2 ( Fig. 1c,d ) and promoted IRF3 phosphorylation and expression of the anti-inflammatory cytokine IL10 (Fig. 1e) , which are both known to contribute to immune tolerance in the lung 18 . Tα1 also rescued defective IDO1 expression when administered in vivo to C57BL/6 mice homozygous for a Cftr allele encoding p.Phe508del (Cftr F508del/F508del mice; hereafter referred to as Cftr F508del mice) infected with Aspergillus fumigatus, which colonizes CF airways and contributes to chronic lung disease 25 . Mice received Tα1 either intraperitoneally or intranasally ( Supplementary Fig. 1a,b ) soon after infection or in an established infection model ( Supplementary Fig. 1c-e ) daily for 6 d at 200 µg per kg bodyweight, which is a dose previously shown to exert therapeutic activity in preclinical settings 26 and to approximate, on a weightper-weight basis, Tα1 doses that can be safely administered to humans 27 . Tα1 restored IDO1 expression both basally and after infection ( Fig. 1f and  Supplementary Fig. 1a ) and concomitantly reduced caspase-1 cleavage ( Fig. 1g ) and NLRP3 expression (insets of Fig. 1h ), thus reducing inflammasome activity. At the same time, it reduced lung pathology in naive and infected mice ( Fig. 1h and Supplementary Fig. 1d ), fungal colonization ( Fig. 1i and Supplementary Fig. 1c ) and neutrophil infiltration ( Fig. 1j and Supplementary Fig. 1b,e ). Levels of the inflammatory cytokines tumor necrosis factor (TNF)-α, IL-1β and IL-17A were all reduced, and IL-10 levels, as well as those of IL-1Ra, were increased by Tα1 ( Fig. 1k and Supplementary Fig. 1b,e ), which suggests that Tα1-via IDO1 induction-may also restrain pathogenic inflammasome activity in CF 28 . Similar results were obtained in Cftr +/− and Cftr −/− mice ( Supplementary  Fig. 2a-d) , indicating that the anti-inflammatory activity of Tα1 occurs independently of CFTR expression and function. Tα1 also restrained inflammation and lung colonization in Pseudomonas aeruginosa infection ( Supplementary Fig. 2e-g) , indicating that it might favorably affect microbial composition in the CF-infected lung.
A limited but significant increase in bodyweight was afforded by Tα1 treatment in knockouts ( Supplementary Fig. 3a) , which prompted us to examine the effects of Tα1 on gut morphology in mutant mice, while also considering that loss-of-function mutations of Cftr cause intestinal pathology 29 . Similar to what was observed in the lung, Tα1 rescued IDO1 expression, tissue architecture, barrier function and cytokine balance in the small intestines of Cftr F508del mice ( Supplementary Fig. 3b-e ). This further suggested that Tα1, by influencing CF inflammation and microbiology, favorably alters the natural history of the disease.
Ta1 improves the localization and stability of mutant CFTR Infection and inflammation may produce secondary alterations in CFTR expression and function 30 . This might imply that efficient control of inflammation would improve CFTR functioning. Considering that IDO1 is a potent driver of autophagy 31 and that restoring disabled autophagy in CF will rescue CFTR function 9,32 , we interrogated whether Tα1 treatment would also affect CFTR functioning. We found that Tα1 favored trafficking of mature CFTR in CFBE41o-cells stably expressing p.Phe508del-CFTR. CFTR exit from the endoplasmic reticulum, passage through the Golgi and delivery of the mature form (band C) to the cell surface are accompanied by an increase in molecular weight (from 135-140 to 170-180 kDa) as a result of glycosylation. At a clinically attainable dose 33 , Tα1 increased cellular expression of mature p.Phe508del-CFTR ( Fig. 2a , band C) by 10-fold ± 0.5-fold (s.d.) relative to vehicle-treated cells ( Fig. 2b) , reaching levels as high as 52 ± 7% of control values. The effect was observed at 30 min and up to 24 h after treatment ( Fig. 2a) , was dose dependent ( Fig. 2c) and was still somewhat detectable at 12 h after Tα1 removal ( Fig. 2d) .
Low-temperature treatment of airway cells harboring the p.Phe508del-CFTR mutation alleviates the processing defect of the mutant protein, enhancing its plasma membrane localization 34 . Tα1 increased plasma membrane localization of p.Phe508del-CFTR to the half-maximal value afforded by low-temperature incubation ( Fig. 2e,f) , as revealed by immunoblotting of purified plasma membrane fractions (FLOT-1 + ) with anti-CFTR antibody (Fig. 2g,h ) and immunofluorescence staining ( Fig. 2i) . We found clear restriction of p.Phe508del-CFTR proteins around the nucleus in untreated CFBE41o-cells, in opposition to the mutated protein's migration to the plasma membrane after Tα1 treatment. This suggested that Tα1 increases the conformational stability of p.Phe508del-CFTR in the ER, thus allowing its exit from the ER and its trafficking to the cell surface. This was confirmed by the limited proteolysis assay, which measures resistance to proteolytic digestion of folded versus unfolded proteins 35 . Tα1 reduced the proteolytic digestion of p.Phe508del-CFTR ( Fig. 2j) .
As Rab GTPases modulate the intracellular trafficking of CFTR through the endosomal and recycling compartments 36 , we performed immunostaining of p.Phe508del-CFTR with markers of early (Rab5), late (Rab7) and recycling (Rab9) endosomes after Tα1 exposure. Tα1 reduced colocalization of mutant CFTR with Rab5 and Rab7, and it instead promoted colocalization with Rab9 ( Fig. 2k) , indicating that Tα1 reduces endocytic recycling through VOLUME 23 | NUMBER 5 | MAY 2017 nAture medicine 
Casp-1 p10 the early endosomes, prevents movement to the late endosomes and/ or lysosomes and favors recycling from the endosomes to the plasma membrane. Thus, Tα1 facilitates proper folding and trafficking of p.Phe508del-CFTR and also stabilizes the rescued CFTR mutant protein at the plasma membrane.
Ta1 rescues CFTR protein through USP36 deubiquitination and autophagy Next, we measured the half-life of p.Phe508del-CFTR in CFBE41o-cells treated with Tα1 for 24 h at 37 °C. Tα1 did not increase steady-state CFTR mRNA expression (data not shown) and marginally affected the half-life of wild-type (WT) CFTR, but it significantly increased the half-life of p.Phe508del-CFTR, which was shorter (1 h) than that of WT CFTR (4 h) ( Fig. 3a,b) . The effect of Tα1 could not be traced to inhibition of the proteasomal and lysosomal degradation pathways, as Tα1 did not inhibit degradation of reporter substrates ( Supplementary  Fig. 4a,b ). However, Tα1 was detected in immunoprecipitated p.Phe508del-CFTR from CFBE41o-cells that overexpressed Tα1 or were treated with Tα1 for 2 h at 37 °C. While present in bronchial epithelial cells expressing WT CFTR, Tα1 was not detected in immunoprecipitated (control)), as quantified by densitometry for the cells in e (100 ng/ml Tα1). (g) Representative immunoblots (n = 3) of CFTR and FLOT-1 (an integral membrane protein) for purified plasma membranes from CFBE41o-cells incubated with Tα1 at 37 °C. (h) Ratio of plasma membrane CFTR/total CFTR as quantified by densitometry of cells exposed as in g. (i) Immunofluorescence staining of CFTR (n = 5 images per treatment) in CFBE41o-cells transfected with mutant CFTR and treated with Tα1 for 24 h. (j) Immunoblots of CFTR in CFBE41o-cells transfected with mutant CFTR and treated with Tα1 for 24 h at 37 °C and exposed to trypsin. (k) Immunostaining of CFTR with Rab5, Rab7, or Rab9 (n = 5 images per treatment) in CFBE41o-cells transfected with mutant CFTR and treated with Tα1 at 37 °C for 2 h. Shown are merged images of cells. See Supplementary Figure 10 WT CFTR ( Supplementary Fig. 5a,b ). Overexpression of Tα1 increased CFTR maturation (Supplementary Fig. 5c ) and IL10 expression and decreased IL6 expression ( Supplementary Fig. 5d ),
suggesting functional Tα1 activity. In accordance with the ER localization of Tα1 that is different from that of its precursor, prothymosin 37 , these results indicate that Tα1 associates with p.Phe508del-CFTR, suggesting a chaperone activity of Tα1 that may affect the protein's ER quality control and degradation. Tα1 perturbed the physical interaction of p.Phe508del-CFTR with the ER chaperon Hsp70 but not with Hsp90 or calnexin, which are known to assist protein folding or degradation 38 (Supplementary Fig. 5e,f) .
Poorly folded plasma membrane-bound CFTR is subjected to proteolysis by the ER-associated degradation mechanism via the cytosolic ubiquitin (Ub)-26S proteasome system. Ubiquitination was reduced in immunoprecipitated p.Phe508del-CFTR from CFBE41o-cells treated with Tα1 (Fig. 3c) . Most of the ubiquitinated p.Phe508del-CFTR was ~200 kDa in molecular weight. Because the CFTR detected by western blotting was in an ~180 kDa complex and a single ubiquitin has a molecular mass of 8 kDa, it appears that Tα1 reduced multiubiquitination, a signal that targets proteins in early endosomes for lysosomal degradation.
The removal of ubiquitin by deubiquitinating enzymes (DUBs) regulates sorting of ubiquitinated plasma membrane-associated proteins 39 . Using a hemagglutinin-tagged ubiquitin probe engineered to form an irreversible covalent bond with active DUBs 35 , we identified ubiquitin-specific protease 36 (USP36)-which inhibits autophagy of protein aggregates by deubiquitination 40 -as a regulator of deubiquitination events triggered by Tα1. Neither USP36-nor either of the two major p.Phe508del-CFTR DUBs, USP10 (ref. 35 ) and USP19 (ref. 41)-could be detected in Tα1-treated cells (Fig. 3d) . Paralleling the promotion of mature CFTR (Fig. 2) , the induction of USP36 occurred at 30 min after initial exposure and was still present at 24 h of exposure (Fig. 3e) . USP36 associated with immunoprecipitated p.Phe508del-CFTR ( Fig. 3f) and deubiquitinated CFTR in Rab5 + endosomes and even more so in Rab9 + endosomes in Tα1-treated cells (Fig. 3g) . This is in line with the finding that Rab9 enters the endosomal pathway at the transition stage between early Rab5 + and late Rab7 + endosomes and colocalizes to the trans-Golgi network 42 . Depletion of USP36 by RNA interference abrogated the rescuing effect of Tα1 on mature p.Phe508del-CFTR, whereas its overexpression further increased the capacity of Tα1 to rescue mutated CFTR (Fig. 3h) . Thus, the corrector activity of Tα1 correlated with USP36-mediated deubiquitination of CFTR in endosomes, thereby promoting CFTR trafficking to the post-endocytic compartment and more efficient ER export to the cell surface. USP36 was not involved in promotion of IDO1 activity by Tα1 (Fig. 3i) , a finding consistent with the importance of the proteasomal degradation pathway for IDO1 activity 21 and, likewise, arguing for USP36 selectivity in CFTR correction.
The ubiquitin system is deeply influenced by autophagy 43 . Defective autophagy in CF leads to an increased pool of ubiquitinated proteins, including the ubiquitin-binding protein SQSTM1/p62, which is pivotal in the aggresome sequestration of ubiquitinated p.Phe508del-CFTR as well as in p.Phe508del-CFTR disposal from the plasma membrane after rescue 32 . Enforced expression of SQSTM1/p62 lacking the UBA domain stabilizes p.Phe508del-CFTR at the plasma membrane and promotes its recycling 10 . In accordance with the ability of autophagy to rescue CFTR function 9 , Tα1 was able to promote IDO1-dependent autophagy (Supplementary Fig. 6a-d) , to reduce SQSTM1/p62 levels (Supplementary Fig. 6e ) and, notably, to correct CFTR in an autophagy-dependent manner, as indicated by the decreased rescue activity in mice bearing Cftr F508del in a Becn1 +/− haploinsufficient background, which confers a major autophagy defect 9 (Supplementary Fig. 6f ).
T1 increases p.Phe508del-CFTR and CLCA1 function
The corrector and stabilizing capacity of Tα1 would anticipate increased chloride ion channel function of the rescued p.Phe508del-CFTR.
We treated p.Phe508del-CFTR-transfected CFBE41o-cells with Tα1 for either 2 or 24 h at 37 °C before determining the channel open probability (P o ) of p.Phe508del-CFTR. Studies have estimated that the extent of correction in p.Phe508del airway epithelial cells must approximate 20-30% of WT CFTR function to provide therapeutic benefit 44 . Treatment with Tα1 for 2 h restored channel gating of rescued p.Phe508del-CFTR (Fig. 4a) with a fourfold increase in P o , namely, from 0.08 ± 0.02 of untreated CFTR to 0.35 ± 0.07 after treatment (Fig. 4b) , with the latter P o values being similar to those for WT CFTR 45 . A twofold increase in chloride current density was still observed at 24 h after treatment as assessed by whole-cell patchclamp recordings of cells expressing p.Phe508del-CFTR (Fig. 4c,d) , and the rate of iodide efflux would then approximate 70% of the control value in WT cells, as assessed by the halide-sensitive fluorescent probe 6-methoxy-N-(sulfopropyl)quinolinium after stimulation with forskolin ( Fig. 4e) . This was confirmed by the results obtained in human bronchial epithelial (HBE) cells from a subject with two distinct mutations, p.Gly1244Glu and p.Phe508del, whereby a gating defect 46 occurred in association with the p.Phe508del defect. The effect of Tα1 was qualitatively similar, although of a lesser extent, to that obtained with potentiator ivacaftor (Fig. 4f) , which is known to restore channel activity in CFTR gating (class III) mutations, including the p.Gly1244Glu mutation 47 . This is in agreement with recent evidence indicating that proteostasis regulators rescue functional CFTR expression in human and mouse cells bearing only one copy of the p.Phe508del allele 9 .
Bypassing CFTR by targeting additional ion channels is an alternative strategy to circumvent the CFTR defect 48 . On the basis of data gathered from DNA microarray analysis of Tα1-treated mice (Supplementary Fig. 7a,b) , we assessed whether Tα1 would increase mRNA expression of the calcium-activated chloride channel regulator 1 (CLCA1), a member of the CLCA protein family capable of paracrine modulation of the activity of TMEM16A 49 , an alternative chloride channel that could obviate the primary defect in CF 48 . Tα1 potentiated calcium-activated chloride currents (Fig. 4g,h) and persistently increased the expression of CLCA1 (Fig. 4i) in CFBE41o-cells. Depleting CLCA1 with specific small interfering RNAs (siRNAs) (Supplementary Fig. 7 ) greatly reduced the ion channel activity promoted by Tα1 (Fig. 4e) . These findings suggested that Tα1 is endowed with effects that can further ameliorate chloride channel activity in CF.
Ta1 rescues p.Phe508del-CFTR in mice and HBE cells
To determine whether Tα1 corrects CFTR in vivo, we assessed CFTR expression and activity in Cftr F508del C57BL/6 mice aged 4 weeks treated daily for 6 d with 200 µg of Tα1 per kg of bodyweight. Tα1 restored CFTR expression in the lung (Fig. 5a,b) and small intestine ( Fig. 5c,d) , as assessed by immunoblotting of cell lysates (Fig. 5a,c) , and it promoted localization of mature CFTR to the plasma membrane ( Fig. 5b,d) , as revealed by immunohistochemistry. Functionally, Tα1 treatment restored channel gating in lung epithelial cells with a twofold increase in P o from 0.23 ± 0.02 before stimulation to 0.45 ± 0.04 after forskolin and genistein stimulation (Fig. 5e,f) . In intestines from Cftr F508del mice mounted in Ussing chambers, Tα1 significantly increased CFTR-dependent chloride ion conductance in response to forskolin, much like the proteostasis regulator cysteamine 9 (Fig. 5g,h) . Rescue of CFTR activity by Tα1 was also observed in Cftr F508del mice on an FVB/129 background (data not shown). Of interest, Tα1 also increased CLCA1 expression in both the lung (Fig. 5i,j) and the gut (Fig. 5k,l) of Cftr F508del mice. VOLUME 23 | NUMBER 5 | MAY 2017 nAture medicine Taken together, these data indicated that administration of Tα1 ameliorated chloride ion fluxes in the intestinal and respiratory tracts of Cftr F508del mice.
To test the activity of Tα1 in a more relevant clinical setting, HBE cells from five subjects homozygous for the p.Phe508del-CFTR mutation were assessed for CFTR, USP36 protein levels and CLCA1 gene None Tα1
None Tα1
CFTR None Tα1
None Tα1 ** expression after exposure to Tα1 for 24 h at 37 °C. Tα1 increased expression of the mature p.Phe508del-CFTR protein (Fig. 6a) , USP36 (Fig. 6b) and CLCA1 (Fig. 6c) in three of the five subjects with CF and concomitantly increased ion channel activity (Fig. 6d) . To assess the clinical relevance of these findings, we measured the concentrations of Tα1 in sputa from subjects with the p.Phe508del-CFTR mutation and control subjects, taking into consideration that Tα1 is highly expressed not only in human thymic epithelium 50 but also in peripheral tissues 33 . We found lower concentrations of Tα1 in subjects with CF than in controls ( Fig. 6e) , which is consistent with the lower levels observed in supernatants and lysates from p.Phe508del-CFTR-transfected CFBE41o-cells relative to cells transfected with WT CFTR (Fig. 6f) .
Because signaling via TLRs influences Tα1 production by lung epithelial cells (Supplementary Fig. 8 ), the deregulated TLR activity observed in subjects with CF 13 may affect local Tα1 production and, ultimately, CFTR activity. This likely occurs, as endogenous Tα1 affected functional expression of CFTR. We assessed the expression of mature CFTR in HBE cells from subjects with the p.Phe508del-CFTR mutation and controls after prothymosin depletion (by specific siRNA) or overexpression (via transfection) because Tα1 is produced by cleavage of prothymosin by the lysosomal asparaginyl endopeptidase legumain 37 . We found that mature p.Phe508del-CFTR expression was negated by prothymosin inhibition and increased by prothymosin overexpression (Fig. 6g) . Of interest, prothymosin overexpression also increased mature CFTR expression in cells from controls (Fig. 6g) , which points to a role for the endogenous prothymosin/Tα1 system in CFTR physiology. We finally comparatively assessed the ion channel activity of Tα1 with that of lumacaftor or ivacaftor, either alone or in combination, in primary HBE cells from controls or subjects homozygous for the p.Phe508del-CFTR mutation. Ussing chamber tracings revealed that Tα1 promoted the forskolin-induced increase in the chloride current (Isc) in HBE cells from subjects with CF ( Fig. 6h) but not controls (Fig. 6i) , an effect that was sensitive to CFTR inhibition and was similar to that observed with lumacaftor ( Fig. 6j) . With the only exception of subject 8 (Supplementary Fig. 9 ), the activity of Tα1 was not additive to that of ivacaftor, which is unable to rescue p.Phe508del-CFTR at the plasma membrane 47 . Similar results were obtained by means of a halide-sensitive fluorescent probe (Supplementary Fig. 9 ). In spite of the reported interindividual variability, even in patients bearing the same genotype, these results suggest that Tα1 alone or in combination can be used for treating subjects with the p.Phe508del-CFTR mutation.
DISCUSSION
While regulation of lung homeostasis and inflammation by CFTR is an established notion 51 , whether regulation of inflammation will affect CFTR functioning is less clear. Here we show that Tα1 is endowed with the unique ability to correct CFTR defects through the regulation of inflammation. Although Tα1 appears to have a multitasking chaperon activity through which it may affect the balance of protein folding versus degradation (for example, by associating with p.Phe508del-CFTR, perturbing the interaction of mutated CFTR with the ER chaperons and activating USP36-mediated deubiquitination of misfolded CFTR), the induction of IDO1 appears to be key to this mechanism. IDO1 is known to play a major role in preventing excessive pathology in immune-mediated tissue injury through multiple effector mechanisms, including the induction of autophagy 31 . In accordance with the ability of autophagy to rescue CFTR function 9 , the promotion of autophagy appeared to contribute to the corrector activity of Tα1 and qualified Tα1 as a proteostasis regulator that rectifies an unbalanced degradasome activity in CF cells. Proteostasis regulators, such as cysteamine, have emerged as a new option for CFTR repair by avoiding unwanted protein-protein interactions, favoring the trafficking and stability of mutant CFTR and hence controlling inflammation 9,10,32 . Unlike cysteamine, the anti-inflammatory effects of Tα1 are not dependent on an ability to rescue functional p.Phe508del-CFTR, as they also occur in CFTR-knockout mice. Therefore, Tα1 is an excellent example of a drug with primary anti-inflammatory effects that can also favor rescue of p.Phe508del-CFTR.
The cross-regulation between autophagy and inflammasomes 52 may also explain the ability of Tα1 to inhibit NLRP3-based inflammasome activity, which is known to contribute to respiratory infections and pathologic airway inflammation in CF 28 . Moreover, as immune tolerance induced by IDO1 includes tissue repair and remodeling activity 53 , this may explain the remarkable effect of Tα1 in restoring host tissue architecture in the lung and the gastrointestinal tract of Cftr F508del mice. Similarly to subjects with CF 30 , an altered pulmonary histopathophysiology is present in those mice in the absence of infection 54 . Altogether, these findings may point to Tα1 as a drug candidate capable of preventing CF progression at very early stages of the disease.
Through its multitasking activity, Tα1 may represent a proper means of rectifying the multifunctional defect in individuals with CF, including the increase in CLCA1 activity. Both clinical and animal model studies have suggested a compensatory role for CLCA1 in CF 55, 56 . Even though calcium-activated chloride channels are abundant in mouse but not in human airways 48, 57 , mutations in CLCA1 are found in a subset of people with CF marked by aggravated intestinal disease 55 , a finding consistent with the observation that calcium-activated chloride channels are defective in the intestine of individuals with CF 57 . This may explain the remarkable activity of Tα1 in the gastrointestinal tract of Cftr F508del mice, in which chloride channel activity was rectified. This indicates that Tα1 could be clinically exploited for pharmacologic correction of defective CFTR not only in the lung but also in the gut, implying that gastrointestinal outcome measures could be promising clinical endpoints of Tα1 therapeutics.
Only a combination of molecules with different mechanisms of action is expected to induce a considerable degree of p.Phe508del-CFTR correction, as shown by the combination of ivacaftor with lumacaftor 6,58 or VX-661 (refs. 59,60) . Although the corrector activity of Tα1 has yet to be verified relative to the agents moving into development in the clinic, the excellent safety profile and cost effectiveness of Zadaxin in adults and children 20 suggest that Tα1 could be tested in clinical trials for possible pulmonary and extrapulmonary benefits in individuals with CF.
URLs. List of CF-associated mutations, http://www.genet.sickkids. on.ca/cftr/StatisticsPage.html.
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